|
 |
Sodium PhenylbutyrateThis page contains recent news articles, when available, and an overview of Sodium Phenylbutyrate but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Injection 10%/10%, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder, the LIPOSONIX(TM)(1) system and the over-the-counter brand ESOTERICA(R). ... CNNMoney.com (press release) Medicis Reports Third Quarter 2009 Financial Results - Nov 4, 2009 Injection 10%/10%, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder, the LIPOSONIX(R)(1) System and the over-the-counter brand ESOTERICA(R). ... CNNMoney.com (press release) Medicis Announces Third Quarter 2009 Conference Call and Webcast - Nov 2, 2009 Injection 10%/10%, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder, the LIPOSONIX(R)(1) System and the over-the-counter brand ESOTERICA(R). ... Reuters Sodium Phenylbutyrate (Systemic). - Aug 1, 2006 Sodium phenylbutyrate (SOE-dee-um fen-il-BYOO-ti-rate) is used to help treat a deficiency of enzymes that help remove ammonia from your body. ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com New FDA Orphan Drugs: Sodium Phenylbutyrate, MGCD0103, … - Sep 7, 2007 September 7, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation for sodium phenylbutyrate for the treatment of spinal ... Medscape Somanta Signs Letter of Intent to Expand Sublicense Agreement with … - Dec 12, 2006 Sodium Phenylbutyrate (PB) is a safe, well-tolerated compound that has been used in a ... Somanta's lead clinical product is Sodium Phenylbutyrate (PB), ... Genetic Engineering News - Genetic Engineering News (press release) Utah study is offering hope for ill children | Article from Deseret... - May 6, 2005 Sodium phenylbutyrate has been used for years to treat certain metabolic ... Swoboda has used sodium phenylbutyrate in children under 2 for a couple of ... Pay-Per-View - Deseret News - HighBeam Research Experimenting with life - Feb 4, 2005 Lucas is being treated with a similar drug, sodium phenylbutyrate, said Pat Quiroz, ... "(Sodium phenylbutyrate) corrects the malfunction in the cells and ... $3.50 - The Gazette - NewsBank Predicting gene promoter methylation in non-small-cell lung cancer by... - Jan 11, 2007 Specifically, treatment with 5-azacytidine followed by the HDAC inhibitor, sodium phenylbutyrate, was associated with induction of acetylation of histones ... Nature.com Prolonged molecular remission in PML-RAR-positive acute promyelocytic... - Jul 21, 2005 7 Although initial results were promising, 4 sodium phenylbutyrate proved ineffective in a further four patients. 7 Owing to the uncertainty of response to ... Nature.com Families of SMA and Tikvah Therapeutics, Inc. Establish Collaboration... - Aug 28, 2007 ..."Testing of Sodium Phenylbutyrate has been hampered by the unpleasant taste, smell and large bulk of poorly soluble preparations," said Lou Barbato, MD, ... RedOrbit Hyperion Therapeutics Announces Enrollment of First Patient in Phase... - Oct 23, 2007 The phase 1/2 study is designed to evaluate the safety, tolerability and ammonia scavenging effects of GT4P compared to BUPHENYL(R) (sodium phenylbutyrate) ... Free with registration - PR Newswire - AccessMyLibrary.com Somanta Signs Cancer Drug Development Agreement With University of … - Sep 19, 2006 Sodium Phenylbutyrate (PB) is a safe, well-tolerated compound that has been used in a small pediatric indication, hyperuremia, for many years. ... RedOrbit Brookwood Pharmaceuticals Inc acquires Alkermes Inc-External Polymer ... - Jan 19, 2005 Particles For Injectable Suspension) Access Pharmaceuticals, Inc. ( ACCP ) Products: ProLindac (DACH Polymer Platinate) Somanta Sodium Phenylbutyrate/VP###… ... Pay-Per-View - deals - Alacra Store Medicis Announces FDA Approval of AMMONUL for Urea Cycle Disorder. - Feb 18, 2005 BUPHENYL(R) (sodium phenylbutyrate), another Medicis prescription product indicated for UCD, is the only FDA-approved drug for maintenance treatment of UCD ... Free with registration - Business Wire - AccessMyLibrary.com Somanta to Hold Business Update Conference Call and Webcast on … - Aug 30, 2006 Sodium Phenylbutyrate (PB) is a safe, well-tolerated compound that has been used in a small pediatric indication, hyperuremia, for many years. ... $4.95 - Business Wire - ECNext Somanta Completes Registration Process and Receives Stock Trading … - Sep 15, 2006 Sodium Phenylbutyrate (PB) is a safe, well-tolerated compound that has been used in a small pediatric indication, hyperuremia, for many years. ... $4.95 - Business Wire - ECNext Medicis to Present At RBC Capital Markets Healthcare Conference - Dec 10, 2007 ...and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium ... Bloomberg Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem … - Jul 10, 2008 4-thio Ara-C, which is a next generation nucleoside analogue licensed from Southern Research Institute and sodium phenylbutyrate, which is licensed from ... RedOrbit Medicis Declares Cash Dividend - Dec 12, 2007 ...and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium ... Bloomberg Combination therapy with DNA methyltransferase inhibitors in … - Aug 16, 2005 ...(2004) Changes in promoter methylation and gene expression in patients with MDS and MDS-AML treated with 5-azacitidine and sodium phenylbutyrate [abstract]. ... Nature.com Netherlands Corporate News - Ipsen and Medicis Announce Acceptance … - May 19, 2008 ...(sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), prescription products indicated in the treatment of Urea Cycle Disorder, Netherlands Corporate News - Netherlands Corporate News (persbericht) Analysis: Virtually Zero Alternative Cancer Research Occurring - Apr 28, 2008 It turns out that 24 of these 123 trials actually focused on a combination of natural compounds and the drug sodium phenylbutyrate, and are only classified ... Natural News.com Scientists Discover Why Animal Studies May Lead to Ineffective ALS … - Jan 22, 2008 Their results showed the compounds minocycline, creatine, ritonavir, celecoxib, sodium phenylbutyrate, ceftriaxone, WHI-P131, thalidomide, and riluzole had ... Free with registration - PR Newswire - AccessMyLibrary.com Dallas-based Access Pharmaceuticals to acquire MacroChem Corp. - Jul 11, 2008 4-thio Ara-C, which is a next generation nucleoside analogue licensed from Southern Research Institute and sodium phenylbutyrate, which is licensed from ... Pegasus News Medicis and Ipsen Decide to Focus Partnership for Reloxin Exclusively... - Jul 12, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis Declares Cash Dividend - Sep 17, 2008 ...and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder and AMMONUL(R) (sodium ... RedOrbit Press Release: Hyperion Therapeutics Announces Enrollment of First … - Oct 23, 2007 The phase 1/2 study is designed to evaluate the safety, tolerability and ammonia scavenging effects of GT4P compared to BUPHENYL(R) (sodium phenylbutyrate) ... Pay-Per-View - PR Newswire - HighBeam Research Ipsen to Grant Medicis Rights to Distribute and Promote Ipsen's... - Mar 13, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Utah study is offering hope for ill children - May 5, 2005 ...in the early phase clinical trials testing new use of two proven medications — sodium phenylbutyrate and valproic acid combined with carnitine. ... deseretnews.com Medicis Announces First Quarter 2008 Conference Call and Webcast - May 6, 2008 ...and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium ... RedOrbit NEA Participates in $40M Investment in Hyperion Therapeutics. - Sep 5, 2007 ...compounds for the treatment of UCD, AMMONUL([R])(sodium phenylacetate and sodium benzoate) Injection 10%/10% and BUPHENYL([R]) (sodium phenylbutyrate). ... Free with registration - Business Wire - AccessMyLibrary.com Reloxin Agreement Between Ipsen and Medicis Becomes Effective - Mar 20, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis to Present at Thomas Weisel Partners Healthcare Tailwinds... - Sep 6, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... RedOrbit MacroChem Acquires Virium Pharmaceuticals - Apr 23, 2008 Virium's VP101 development program involves an amino acid derivative commonly known as sodium phenylbutyrate ("PB"). Through sponsorships with the National ... Lifescience-online Medicis and Revance Announce Strategic Collaboration - Dec 11, 2007 ...and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium ... RedOrbit Medicis to Present At Morgan Stanley Pharmaceutical CEOs Unplugged … - Dec 29, 2006 BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), prescription products indicated in the treatment of Urea ... RedOrbit Schillings boost fundraiser - Nov 2, 2005 Two drugs, valproic acid and sodium sodium phenylbutyrate, are in phase II trials at the FDA, he said, with proven results in treating the disease. ... wickedlocal.com Medicis to Present At Citi Investment Research Healthcare Conference - May 19, 2008 0.1%, and ZIANA(R)(clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R)(sodium phenylbutyrate) and AMMONUL(R)(sodium phenylacetate/sodium ... RedOrbit PRESS RELEASE: Hyperion Therapeutics Announces Senior … - Oct 4, 2007 ...dermatology (Dynacin®), respiratory (Azmacort®, Intal®, and Orapred®) and rare metabolic disorders (AMMONUL and BUPHENYL® (sodium phenylbutyrate)). ... FierceBiotech Medicis Announces FDA Approval of SOLODYN -- minocycline HCl, USP … - May 8, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com MacroChem acquires Virium Pharmaceuticals - Apr 18, 2008 Virium's VP101 development program involves an amino acid derivative commonly known as sodium phenylbutyrate ("PB"). Through sponsorships with the National ... News-Medical.net Medicis Requests That Inamed Recommend Rejection of Allergan … - Nov 22, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... RedOrbit Netherlands Corporate News - Ipsen and Medicis Announce Submission … - Jun 12, 2007 ...and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium ... Netherlands Corporate News - Netherlands Corporate News (persbericht) Medicis to Present At Goldman Sachs Global Healthcare Conference - Jun 6, 2008 ...and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium ... RedOrbit Medicis Names Jason Hanson Executive Vice President and General … - Jul 12, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis and BioMarin Reach Settlement. - Jan 12, 2005 ...over-the-counter brand ESOTERICA(R), and BUPHENYL(R) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder. ... Free with registration - Business Wire - AccessMyLibrary.com Somanta Announces Data to Be Presented on Angiolix for Targeting … - Jan 31, 2007 Somanta's lead clinical product is Sodium Phenylbutyrate (PB), for which it is scheduling and planning a Phase IIb clinical trial involving a central ... Genetic Engineering News - Genetic Engineering News (press release) 5K boosts hopes for SMA research - May 20, 2008 As one of Swoboda's patients, Taylor is part of a clinical trial involving valproic acid and sodium phenylbutyrate, two drugs which have shown promise in ... Midlothian Exchange Medicis Announces Third Quarter 2006 Conference Call and Webcast - Nov 6, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Urea Cycle Disorder; Pharmaceutical company obtains FDA approval of … - Mar 21, 2005 BUPHENYL (sodium phenylbutyrate), another Medicis prescription product indicated for UCD, is the only FDA-approved drug for maintenance treatment of UCD ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones Ipsen And Medicis Announce Submission Of Reloxin(R) In Aesthetics To ... - Dec 7, 2007 ...and ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL® (sodium phenylbutyrate) and AMMONUL® (sodium phenylacetate/sodium benzoate), ... Medical News Today - Medical News Today (press release) Medicis Announces Second Quarter 2006 Conference Call and Webcast - Jul 31, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis Announces Second Quarter 2008 Conference Call and Webcast - Jul 31, 2008 ...and ZIANA(R) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) Tablets and Powder and AMMONUL(R) (sodium ... RedOrbit Access Pharmaceuticals Hones in on Oncology Focus with Acquisition - Feb 21, 2007 Somanta's Phase II product, sodium phenylbutyrate (PB), is being evaluated for recurrent glioblastoma and prostate cancer. ... Genetic Engineering News - Genetic Engineering News (press release) Medicis to Present At Thomas Weisel Partners Healthcare Conference - Sep 5, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com OutSystems Accelerates Hyperion Therapeutics' Go-to-Market - Jun 24, 2008 ...and co-promotion agreement for AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10% and BUPHENYL(R) (sodium phenylbutyrate), ... Genetic Engineering News - Genetic Engineering News (press release) Medicis to Present at Merrill Lynch 16th Annual Global Pharmaceutical,... - Feb 7, 2005 ...over-the-counter brand ESOTERICA(R), and BUPHENYL(R) (sodium phenylbutyrate), a prescription product indicated in the treatment of Urea Cycle Disorder. ... $4.95 - Business Wire - ECNext Published E-Letter responses: - Apr 18, 2007 ...sodium phenylbutyrate (1), depudecin (2), and carbamazepine (3). Additionally, dexamethasone is also known to cause a decrease in nuclear expression and ... Science Magazine - Science Magazine (subscription) Medicis to Present at Morgan Stanley 2006 Global Healthcare Unplugged... - Apr 28, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Press Release: Hyperion Therapeutics Completes Phase 2 Data Analysis … - Nov 12, 2008 ...ammonia scavenging effects of HPN-100 versus BUPHENYL(R) (sodium phenylbutyrate), the current standard of care in patients with urea cycle disorders. ... Pay-Per-View - PR Newswire - HighBeam Research Medicis to Present at Merrill Lynch 17th Annual Global Pharmaceutical,... - Feb 3, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... RedOrbit Medicis to Present at 24th Annual JPMorgan Healthcare Conference - Jan 6, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... RedOrbit Medicis Declares Cash Dividend - Mar 15, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis Announces FDA Approval of Broader Indication for VANOS - Mar 2, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Stem Cell Clinic Applauds Breakthrough - Jun 8, 2007 ..."These studies provide strong support for the possibility of using currently available medicines such as valproic acid or sodium phenylbutyrate, which act ... Genetic Engineering News - Genetic Engineering News (press release) Medicis to Present at Wachovia Securities Equity Conference - Jun 14, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com (Euronext Paris) - Ipsen : Medicis and Ipsen decide to focus partnersh... - Dec 7, 2006 VANOS™ (fluocinonide) Cream, 0.1%, and SYNALAR® (fluocinolone acetonide), BUPHENYL® (sodium phenylbutyrate) and AMMONUL® (sodium phenylacetate/sodium ... euronext.com Medicis Announces First Quarter 2006 Conference Call and Webcast - May 4, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis to Present at Credit Suisse Healthcare Conference - Nov 13, 2006 BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), prescription products indicated in the treatment of Urea ... primezone.com Medicis Declares Cash Dividend - Sep 14, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis to Present At CIBC World Markets Healthcare Conference - Nov 3, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis Begins Shipping PERLANE to Physicians - May 21, 2007 ...and ZIANA(TM) (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel, BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium ... RedOrbit Medicis to Host Conference Call and Webcast from ASPS - Oct 6, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis to Present at UBS Global Life Sciences Conference - Sep 22, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis to Present at Deutsche Bank 31st Annual Health Care … - Apr 27, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis Announces Two Patents Issued for LOPROX Gel - Apr 12, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis to Present at Goldman Sachs Global Healthcare Conference - Jun 8, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide); BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate); ... primezone.com Medicis Announces December 2005 Quarter-End Conference Call and … - Mar 10, 2006 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... primezone.com Medicis to Present at Banc of America Securities 2005 Specialty … - Jul 25, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... $4.95 - Business Wire - ECNext Stem Cell Clinic Applauds Breakthrough. - Jun 9, 2007 ..."These studies provide strong support for the possibility of using currently available medicines such as valproic acid or sodium phenylbutyrate, which act ... $4.95 - Business Wire - ECNext Medicis to Present at Thomas Weisel Partners Growth Forum 7.0. - Jun 9, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... $4.95 - Business Wire - ECNext Access Pharmaceuticals Signs Definitive Merger Agreement With … - Apr 19, 2007 Somanta's lead clinical product Sodium Phenylbutyrate (PB) is currently in Phase 2 development and is being developed with its partner, ... $4.95 - PR Newswire - ECNext Urea Cycle Disorder; Pharmaceutical company obtains FDA approval of … - Mar 26, 2005 BUPHENYL (sodium phenylbutyrate), another Medicis prescription product indicated for UCD, is the only FDA-approved drug for maintenance treatment of UCD ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Medicis to Present at Morgan Stanley 3rd Annual Healthcare Unplugged ... - May 2, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... $4.95 - Business Wire - ECNext Urea Cycle Disorder; Pharmaceutical company obtains FDA approval of … - Mar 24, 2005 BUPHENYL (sodium phenylbutyrate), another Medicis prescription product indicated for UCD, is the only FDA-approved drug for maintenance treatment of UCD ... Pay-Per-View - Blood Weekly - Factiva, from Dow Jones Medicis to Present at Deutsche Bank 30th Annual Health Care … - Apr 29, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... $4.95 - Business Wire - ECNext Article: I raised cash for lifesaving drug. - The Evening Standard... - May 11, 2006 ...and virtually ignored by pharmaceutical companies. Without daily doses of a chemical compound called sodium phenylbutyrate, the Forest Park girl would ... Pay-Per-View - Evening Standard - HighBeam Research Hyperion completes Phase II study data analysis for HPN-100 as urea … - Nov 12, 2008 ...and ammonia scavenging effects of HPN-100 versus BUPHENYL (sodium phenylbutyrate), the current standard of care in patients with urea cycle disorders. ... $9.94 - M2 Europharma - Alacra Store Competitors by Product Report - Dec 13, 2008 Access Pharmaceuticals, Inc. (ACCP) Products:. ProLindac (DACH Polymer Platinate); Somanta Sodium Phenylbutyrate/VP101 ... $75.00 - Revere Reports - Revere Competitors by Product Report - May 10, 2008 Access Pharmaceuticals, Inc. (ACCP) Products:. ProLindac (DACH Polymer Platinate); Somanta Sodium Phenylbutyrate/VP101 ... $75.00 - Revere Reports - Revere Competitors by Product Report - Mar 29, 2008 Access Pharmaceuticals, Inc. (ACCP) Products:. ProLindac (DACH Polymer Platinate); Somanta Sodium Phenylbutyrate/VP101 ... $75.00 - Revere Reports - Revere Competitors by Product Report - Jun 21, 2008 Access Pharmaceuticals, Inc. (ACCP) Products:. ProLindac (DACH Polymer Platinate); Somanta Sodium Phenylbutyrate/VP101 ... $75.00 - Revere - Alacra Store Press Release: Hyperion Therapeutics Secures $40 Million In Series B ... - Sep 5, 2007 ...compounds for the treatment of UCD, AMMONUL(R) (sodium phenylacetate and sodium benzoate) Injection 10%/10% and BUPHENYL(R) (sodium phenylbutyrate). ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: REDF, SYMS, ACCP, GNTA, NCEY, NTNI Have Also … - Jul 30, 2008 The company has a co-development and sublicense agreement with Virium Pharmaceuticals, Inc. to develop Sodium Phenylbutyrate, a Phase II clinical candidate ... Pay-Per-View - M2 Presswire - HighBeam Research Competitors by Product Report - Aug 16, 2008 Access Pharmaceuticals, Inc. (ACCP) Products:. ProLindac (DACH Polymer Platinate); Somanta Sodium Phenylbutyrate/VP101 ... $75.00 - Revere Reports - Revere Medicis Declares Cash Dividend. - Jun 15, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... $4.95 - Business Wire - ECNext Press Release: TKO, COLM, TMCV, ACCP, FEEC, PRPL Have Been … - Sep 8, 2008 The company has a co-development and sublicense agreement with Virium Pharmaceuticals, Inc. to develop Sodium Phenylbutyrate, a Phase II clinical candidate ... Pay-Per-View - M2 Presswire - HighBeam Research Press Release: Hyperion Therapeutics Completes Enrollment in Phase 1/... - Jul 22, 2008 ...and ammonia scavenging effects of HPN-100 (formally called GT4P) versus BUPHENYL(R) (sodium phenylbutyrate) in patients with urea cycle disorders (UCD). ... Pay-Per-View - PR Newswire - HighBeam Research Competitors by Product Report - Jun 21, 2008 Access Pharmaceuticals, Inc. (ACCP) Products:. ProLindac (DACH Polymer Platinate); Somanta Sodium Phenylbutyrate/VP101 ... $75.00 - Revere - Alacra Store Competitors by Product Report - Nov 22, 2008 Access Pharmaceuticals, Inc. (ACCP) Products:. ProLindac (DACH Polymer Platinate); Somanta Sodium Phenylbutyrate/VP101 ... $75.00 - Revere Reports - Revere Medicis Declares Cash Dividend. - Sep 14, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... $4.95 - Business Wire - ECNext Medicis Amends and Restates Shareholder Rights Agreement. - Aug 17, 2005 0.1%, and SYNALAR(R) (fluocinolone acetonide), BUPHENYL(R) (sodium phenylbutyrate) and AMMONUL(R) (sodium phenylacetate/sodium benzoate), ... $4.95 - Business Wire - ECNext |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |